Abstract：
Proper hydration and the clarity of the cornea are maintained through the crucial function of the corneal endothelium. Inflammation of the corneal endothelium, known as endotheliitis, can disrupt endothelial function, resulting in alterations to vision. Corneal endotheliitis is characterised by corneal oedema, the presence of keratic precipitates, inflammation within the anterior chamber, and occasionally, limbal injection, neovascularisation, and the concurrent or overlapping presence of uveitis. The aetiology of this condition is diverse, predominantly viral, but it may also be drug-induced, result from bacterial or fungal infections, be associated with systemic diseases and procedures, or remain idiopathic with no identifiable cause. To date, no standardised protocol for the treatment of this ocular disease exists, and in severe cases, corneal transplantation may be required. A 31-year-old male was transferred to our hospital for the management of corneal endothelial decompensation resulting from corneal endotheliitis. Hormonal therapy and antiviral medications proved ineffective, rendering the patient a candidate for corneal transplantation. As a final measure, treatment with the ROCK inhibitor netarsudil was initiated. The patient demonstrated significant improvement in symptoms, and the inflammation was successfully managed after nine months. In this study, a novel approach employing ROCK inhibitor therapy was utilised for the treatment of corneal endotheliitis, leading to marked recovery during patient follow-up. This case report represents the inaugural application of the ROCK inhibitor netarsudil in managing corneal endothelial decompensation attributed to corneal endotheliitis. These findings suggest that this method warrants consideration as a potential novel treatment option for similar conditions.
摘要：
通过角膜内皮的关键功能保持角膜的适当水合和透明度。角膜内皮的炎症，被称为内皮炎，会破坏内皮功能，导致视力的改变。角膜内皮炎以角膜水肿为特征，角质层沉淀物的存在，前房内的炎症，偶尔，角膜缘注射,新生血管化,同时或重叠存在葡萄膜炎。这种情况的病因是多种多样的，主要是病毒，但它也可能是药物诱导的，细菌或真菌感染的结果，与系统性疾病和程序有关，或保持特发性，没有可识别的原因。迄今为止,目前尚无治疗这种眼部疾病的标准化方案，在严重的情况下，可能需要角膜移植。一名31岁的男性被转移到我们的医院，以治疗因角膜内皮炎而导致的角膜内皮代偿失调。激素治疗和抗病毒药物被证明无效，使患者成为角膜移植的候选人。作为最终措施，开始用ROCK抑制剂netarsudil治疗.患者症状明显改善，9个月后炎症得到成功治疗。在这项研究中,一种采用ROCK抑制剂治疗的新方法被用于治疗角膜内皮炎，导致患者随访期间明显恢复。此病例报告代表了ROCK抑制剂netarsudil在治疗归因于角膜内膜炎的角膜内皮代偿失调中的首次应用。这些发现表明，这种方法值得考虑作为类似条件的潜在新型治疗选择。
